
SUPPLEMENTARY MATERIAL

Supplementary Figure 1 (S1). Trans-bronchial biopsyprior tobenralizumab treatment showing eosinophil infiltration at the capillary wall (black arrows - A) and immune-histochemical analysis with an anti-IL-5R α polyclonal antibody showing positive staining of submucosal infiltrating eosinophils (black arrows - B). Trans-bronchial biopsy after benralizumab treatment with no eosinophilic vasculitis (C) and immune-histochemical analysis confirming the absence of IL-5R α -positive cells (D).



J Investig Allergol Clin Immunol 2021; Vol. 31(6): 519-521 doi: 10.18176/jiaci.0689